Product Name:2-Fluoro-6-methoxyphenylboronic acid

IUPAC Name:(2-fluoro-6-methoxyphenyl)boronic acid

CAS:78495-63-3
Molecular Formula:C7H8BFO3
Purity:98%
Catalog Number:CM136989
Molecular Weight:169.95

Packing Unit Available Stock Price($) Quantity
CM136989-1000g in stock ǧƻŴ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:78495-63-3
Molecular Formula:C7H8BFO3
Melting Point:-
Smiles Code:OB(C1=C(OC)C=CC=C1F)O
Density:
Catalog Number:CM136989
Molecular Weight:169.95
Boiling Point:303.1°C at 760 mmHg
MDL No:MFCD02179483
Storage:

Category Infos

Boronic Acids and Esters
Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
Boronic Acid For Sale
Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.
Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Sotorasib
Dec. 26, 2023, Amgen announced that the U.S. FDA has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).
LUMAKRAS (sotorasib) is an oral, first-in-class therapy indicawithted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following at least one previous systemic therapy.
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. The U.S. FDA granted the application for sotorasib orphan drug, fast track, priority review, and breakthrough therapy designations.